ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A Qualitative Signature to Identify TERT Promoter Mutant High-Risk Tumors in Low-Grade Gliomas

Zheng, Weicheng; Zhang, Ruolan; Huang, Ziru; Li, Jianpeng; Wu, Haonan; Zhou, Yuwei; Zhu, Jinwei; Wang, Xianlong*哈尔滨医科大学
Frontiers in Molecular Biosciences2022-4-14DOI: 10.3389/fmolb.2022.806727
1被引6阅读
引用收藏
分享

摘要

Background: Telomerase reverse transcriptase promoter (TERT-p) mutation has been frequently found, but associated with contrary prognosis, in both low-grade gliomas and glioblastomas. For the low-grade gliomas (Grades II-III), TERT-p mutant patients have a better prognosis than the wildtype patients, whereas for the GBMs (Grade IV), TERT-p mutation is related to a poor prognosis. We hypothesize that there exist high-risk patients in LGGs who share GBM-like molecular features, including TERT-p mutation, and need more intensive treatment than other LGGs. A molecular signature is needed to identify these high-risk patients for an accurate and timely treatment.Methods: Using the within-sample relative expression orderings of gene pairs, we identified the gene pairs with significantly stable REOs, respectively, in both the TERT-p mutant LGGs and GBMs but with opposite directions in the two groups. These reversely stable gene pairs were used as the molecular signature to stratify the LGGs into high-risk and low-risk groups.Results: A signature consisting of 21 gene pairs was developed, which can classify LGGs into two groups with significantly different overall survival. The high-risk group has a similar genetic mutation profile and a similar survival profile as GBMs, and these high-risk tumors may progress to a more malignant state.Conclusion: The 21 gene-pair signature based on REOs is capable of identifying high-risk patients in LGGs and guiding the clinical choice for appropriate and timely intervention.

学科与关键词

关键词
gliomaTERT promoterbiomarkertranscriptomerelative expression orderings
相关
加载中…
  • Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients
    Wang, Qi; He, Zongze*; Chen, Yong*Cancer Control, 2019, 26(1): 1073274819855118.
  • TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma
    Gao, Mengqi; Lin, Yi*; Liu, Xing; Zhao, Zheng; Zhu, Zhiyuan; Zhang, Hongbo; Ban, Yunchao; Bie, Yanan; He, Xiaozheng; Sun, Xiang; Zhang, Shizhong*Frontiers in Cell and Developmental Biology, 2021, 9: 654407.被引 10
  • Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI
    Zhang, Hongbo; Zhang, Hanwen; Zhang, Yuze; Zhou, Beibei; Wu, Lei; Lei, Yi*; Huang, Biao*Journal of Magnetic Resonance Imaging, 2023, 58(5): 1441-1451.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Molecular Biosciences
发表日期
2022-04-14
卷期
第 9 卷
页码
806727
DOI
10.3389/fmolb.2022.806727
期刊等级
3区
成果收录
SCIE

作者

  • Z

    Zheng, Weicheng (第一作者)

    harbin med univ · fujian med univ

  • Z

    Zhang, Ruolan

    fujian med univ

查看全部 8 位作者收起作者
  • H

    Huang, Ziru

    fujian med univ

  • L

    Li, Jianpeng

    fujian med univ

  • W

    Wu, Haonan

    fujian med univ

  • Z

    Zhou, Yuwei

    fujian med univ

  • Z

    Zhu, Jinwei

    fujian med univ

  • W

    Wang, Xianlong (通讯)

    fujian med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417